What the business is, and whether it's a good one at a fair price.
Makes complex injectable pharmaceutical products for global markets, with a growing contract development and manufacturing (CDMO) business that accounted for 46% of consolidated revenues in FY26 and grew 28% year-over-year. The base injectables/generics business covers the balance of revenue; the company launched 31 products in the US in FY26, including 5 in Q4 alone, and recently won USFDA approval for Sugammadex Injection. The European CDMO arm, Cenexi, returned to EBITDA positive in Q4 FY26, delivering EUR 182 million in FY26 revenue (+11% YoY). Operations span six domestic plants in India and four international plants, and 88.44% of revenue comes from exports across around 60 countries. The biggest cost line is materials and consumables at 34.8% of revenue, followed by employee costs at 25.3%, with capex planned at INR 500 crore in FY27 and INR 2,000 crore over the next five years.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from GLAND PHARMA LIMITED's filed financials and exchange disclosures
GLAND PHARMA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol GLAND.
Yes. Over the trailing twelve months GLAND PHARMA LIMITED reported a net profit of ₹1,129 Cr on revenue of ₹6,725 Cr.
Yes. The dividend yield is 0.61% at the current price. It paid out 29% of its profit as dividend in FY26.
Effectively yes. It holds ₹3,116 Cr more cash than debt. Debt stands at 0.02× equity.
On trailing P/E, GLAND PHARMA LIMITED ranks 117 of 169 in Pharmaceuticals — cheaper than 31% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session GLAND PHARMA LIMITED moves 0.96% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by GLAND PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
